A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma

Abstract

We developed and translated [¹⁸F]DASA-23 as a new tracer that demonstrated the visualization of aberrantly expressed PKM2 for the first time in human subjects. These results warrant further clinical evaluation of [¹⁸F]DASA-23 to assess its utility for imaging therapy-induced normalization of aberrant cancer metabolism.